<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707300</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191116</org_study_id>
    <secondary_id>2019-004883-23</secondary_id>
    <nct_id>NCT04707300</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)</brief_title>
  <acronym>HTLP-ONCO</acronym>
  <official_title>A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety&#xD;
      and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune&#xD;
      reconstitution after umbilical cord blood (UCB) transplantation in adult patients with&#xD;
      hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated&#xD;
      using a model-based design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic bone marrow transplantation (AlloSCT) is the treatment of choice for high- risk&#xD;
      acute myeloid leukemias in complete first remission after induction therapy. Umbilical cord&#xD;
      blood grafts are frequently used for patients lacking an HLA- matched family donor&#xD;
      (Matched-sibling donor, MSD) as well as in the absence of an appropriate unrelated donor&#xD;
      (10/10 MUD). As any HSCT, UCB transplantations are associated with the risk of acute and&#xD;
      chronic GVHD, post- transplant immunodeficiency with increased risk of infections as well as&#xD;
      relapse. Especially the risk of infection and therefore non- relapse mortality (NRM) or&#xD;
      transplant- related mortality (TRM) is significantly higher in UCB transplantations as&#xD;
      compared to MSD or 10/10 MUD transplantations. All of these risks have been linked to a&#xD;
      significant delay in immune reconstitution including various immune cell populations like CD4&#xD;
      and CD8 T cells, Treg, NK, iNKT, pDC and others.&#xD;
&#xD;
      The investigators therefore make the hypothesis that if T-cell-mediated immunity was rapidly&#xD;
      generated after a partially HLA-compatible UCB transplantation will reduce the risk of&#xD;
      infection and to prevent relapse without increasing the risk of GVHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of grade III-IV graft-versus-host disease (GvHD)</measure>
    <time_frame>100 Days following HSCT</time_frame>
    <description>according to Glucksberg grading system, to define toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 + T cells analysis</measure>
    <time_frame>100 days following HSCT</time_frame>
    <description>Efficacy defined by the presence of &gt;50/μl CD4+ CD3+ TCRαβ+ T cells at 2 consecutive measures &lt; within 4 months post HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of T cell immune reconstitution</measure>
    <time_frame>Month 1, 2, 3, 4, 5, 6 and 12 post-transplantation</time_frame>
    <description>time needed to exceed a count of 100 naive CD4+ and &gt;100 total CD8+ cells per μL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematologic engraftment</measure>
    <time_frame>Up to 24 months post-transplantation</time_frame>
    <description>Time to ANC &gt; 0.5G/L with platelets &gt; 20G/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of neutrophils, platelets and red blood cell transfusions</measure>
    <time_frame>Month 1,2, 3, 6 and 12 post -transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time course of reconstitution of the different T-cell subpopulations</measure>
    <time_frame>Month 1,2, 3, 6 and 12 post -transplantation</time_frame>
    <description>by immunophenotyping (flow cytometry analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Recent thymic emigrants (RTEs)</measure>
    <time_frame>Month 1,2, 3, 6 and 12 post -transplantation</time_frame>
    <description>by immunophenotyping (flow cytometry analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tregs numbers</measure>
    <time_frame>Month 1,2, 3, 6 and 12 post -transplantation</time_frame>
    <description>by immunophenotyping (flow cytometry analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell reconstitution</measure>
    <time_frame>Month 6 and 12 post -transplantation</time_frame>
    <description>number and phenotype for naïve IgD+CD27-, marginal zone IgD+CD27+, switched memory IgD-CD27+, and IgD-CD27- cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin levels</measure>
    <time_frame>Month 6 and 12 post -transplantation</time_frame>
    <description>focus on time needed for cessation of intravenously IgG replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstitution of the NK cell</measure>
    <time_frame>Month 6 and 12 post -transplantation</time_frame>
    <description>compartment (CD3-CD56dimCD16bright)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of engraftment of each UCB unit over time by hematological monitoring and chimerism analysis on neutrophils, T, B, NK, pDC and macrophages at 1, 2, 3, 6 and 12 months following HSCT</measure>
    <time_frame>at 1, 2, 3, 6 and 12 months following HSCT.</time_frame>
    <description>To assess engraftment of each UCB unit over time by hematological monitoring and chimerism analysis on neutrophils, T, B, NK, pDC and macrophages at 1, 2, 3, 6 and 12 months following HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the graft failure/rejection rate</measure>
    <time_frame>3 months following HSCT</time_frame>
    <description>detected by hematological monitoring of each UCB unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of infections</measure>
    <time_frame>3, 6 and 12 months post- transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute and chronic episodes of GVHD and their grade</measure>
    <time_frame>3, 6, 12 and 24 months post-transplantation</time_frame>
    <description>according to Glucksgberg GvHD staging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>2 years post -transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years post -transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years post -transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Myeloid Leukemia (AML) or Minimal Residual Disease (MRD Plus)</condition>
  <arm_group>
    <arm_group_label>Human T Lymphoid Progenitor (HTLP) injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTLP cellular product obtained after 7 days of culture of immune-selected CB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human T Lymphoid Progenitor (HTLP) injection</intervention_name>
    <description>The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0</description>
    <arm_group_label>Human T Lymphoid Progenitor (HTLP) injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years old and &lt;66 years old) at the time of inclusion and&#xD;
             eligible for an allogeneic stem cells transplantation and fit to receive the specified&#xD;
             conditioning regimen&#xD;
&#xD;
          -  High risk AML in CR1 (with t(6;9), t(v; 11q23), t(9;22), Inv(3), t(3;3), abnormalities&#xD;
             of 3q, monosomy 5, 7, 17, complex caryotype, monosomal caryotype, FLT3-ITD (Ratio&#xD;
             ≥O.5) without NPM1 mutations) OR&#xD;
&#xD;
          -  AML with any adverse genetic abnormality, secondary or therapy related AML excluding&#xD;
             good risk genetic abnormalities, or any poor risk feature in CR1 OR&#xD;
&#xD;
          -  High-risk myelodysplastic syndrome (MDS) according to Revised International Prognostic&#xD;
             Scoring System (IPSS-R).&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  MRD+ patients after first line chemotherapy OR&#xD;
&#xD;
          -  Relapsed AML in CR2 OR&#xD;
&#xD;
          -  &gt;=CR2&#xD;
&#xD;
          -  Absence of a matched - related sibling donor (MSD) or a matched unrelated donor (MUD)&#xD;
             10/10&#xD;
&#xD;
          -  SORROR score compatible with the pre specified conditioning and to discuss with the&#xD;
             Principal Investigator&#xD;
&#xD;
          -  Presence of two UCB units with the following criteria*: HLA- matched 6/8, 7/8 or 8/8&#xD;
             for HLA- A, -B, -C and DRB1 loci&#xD;
&#xD;
          -  Presence of at least one UCB unit with the following criteria*: ≥ 3 x 107 TNC/kg or ≥&#xD;
             1.5 105 CD34+/kg pre- freezing * For the UCB taken into HTLP culture, the CD34+&#xD;
             content does not need to meet the above cellularity criteria, as expansion during HTLP&#xD;
             culture has been proven to ensure the appropriate number of CD7+ needed for each dose.&#xD;
&#xD;
        The non- cultured UCB will be chosen to have a higher CD34+ cell content in order to enable&#xD;
        long- term hematopoietic engraftment&#xD;
&#xD;
          -  No prior therapy with allogeneic stem cell transplantation&#xD;
&#xD;
          -  No treatment with another investigational drug within one month before inclusion&#xD;
&#xD;
          -  Patient affiliated to social security&#xD;
&#xD;
          -  Written, informed consent of the patient&#xD;
&#xD;
          -  Absence of Donor Specific Antibodies (DSA) with a MFI &gt; 5000&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous allogeneic stem cell transplantation&#xD;
&#xD;
          -  Any of the standard contraindications to allogeneic transplant&#xD;
&#xD;
               -  Left ventricular ejection fraction &lt;50%&#xD;
&#xD;
               -  Abnormal biochemistry results (ALT/AST&gt;10xULN, total bilirubin&gt;2.5xULN, creatinin&#xD;
                  clearance &lt;60ml/min)&#xD;
&#xD;
          -  Inability to understand and provide informed consent&#xD;
&#xD;
          -  Concomitant infectious disease: HTLV-I, HIV-I or HIV-II&#xD;
&#xD;
          -  Pregnancy or breastfeeding for women of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier HERMINE, PhD &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa MAGRIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Département de Biothérapie : Hôpital Necker Enfants malades</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier HERMINE, PhD &amp; MD</last_name>
    <phone>+33 144495282</phone>
    <email>olivier.hermine@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE, Master</last_name>
    <phone>+33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard FORCADE, PhD &amp; MD</last_name>
      <email>edouard.forcade@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology department / Necker Children's Hospital</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HERMINE, PhD &amp; MD</last_name>
      <phone>+33 144495282</phone>
      <email>olivier.hermine@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Felipe SUAREZ, PhD &amp; MD</last_name>
      <email>felipe.suarez@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>minimal residual disease</keyword>
  <keyword>hematologic malignancies</keyword>
  <keyword>human T Lymphoid Progenitor</keyword>
  <keyword>umbilical cord blood transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

